Sign In
Buy ARDS
$0.0029
+0 (+0%)
At Close: Jun 03, 2026
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where
RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
04:20pm, Tuesday, 31'st Mar 2026
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant Mortality Reductions in ARDS Patients Selection Follows Positive Phase 3 Results for Paridiprubart
JENA, Germany, Jan. 15, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced
Aridis Provides Corporate Update
08:00am, Friday, 20'th Dec 2024
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on re
Aridis Provides Corporate Update
05:58pm, Monday, 24'th Jun 2024
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on re
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
07:30am, Wednesday, 22'nd May 2024
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
04:15pm, Friday, 15'th Dec 2023
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies
Aridis Pharmaceuticals Announces Third Quarter 2023 Financial Results and Business Update
04:15pm, Friday, 03'rd Nov 2023
Received two grant awards from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health
Aridis Pharmaceuticals Announces $2 Million Offering
08:17am, Wednesday, 02'nd Aug 2023
Los Gatos, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies fo
LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company's proposed si
Aridis (ARDS) Up on Receiving FDA's QIDP Designation for AR-301
11:51am, Thursday, 13'th Jul 2023
Aridis (ARDS) achieves a milestone as the FDA granted the Qualified Infectious Disease Product designation for AR-301.
Aridis' AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA's Qualified Infectious Diseases Product (QIDP) Designation
08:00am, Wednesday, 12'th Jul 2023
LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies
Aridis (ARDS) Up on Regulatory Update for Pneumonia Drug
12:34pm, Wednesday, 21'st Jun 2023
Aridis (ARDS) announces that its AR-301 clinical program is eligible for availing the FDA's special pathway for satisfying the unmet medical need of a predefined limited population.
